A citation-based method for searching scientific literature

L Robertson, H Hanson, S Seal, M Warren-Perry, D Hughes, I Howell, C Turnbull, R Houlston, S Shanley, S Butler, D G Evans, G Ross, D Eccles, A Tutt, N Rahman. Br J Cancer 2012
Times Cited: 66







List of co-cited articles
546 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Anne-Renee Hartman, Rajesh R Kaldate, Lisa M Sailer, Lisa Painter, Charles E Grier, Robbin R Endsley, Marlena Griffin, Stephanie A Hamilton, Cynthia A Frye, Mark A Silberman,[...]. Cancer 2012
120
34

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
S R Young, Robert T Pilarski, Talia Donenberg, Charles Shapiro, Lyn S Hammond, Judith Miller, Karen A Brooks, Stephanie Cohen, Beverly Tenenholz, Damini Desai,[...]. BMC Cancer 2009
167
33

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun,[...]. Clin Cancer Res 2011
341
28

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
355
28

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
27


Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
D G Evans, A Howell, D Ward, F Lalloo, J L Jones, D M Eccles. J Med Genet 2011
50
28

Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Janice S Kwon, Angelica M Gutierrez-Barrera, Diana Young, Charlotte C Sun, Molly S Daniels, Karen H Lu, Banu Arun. J Clin Oncol 2010
99
19

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
18

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
18

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
16

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Michelle W Wong-Brown, Cliff J Meldrum, Jane E Carpenter, Christine L Clarke, Steven A Narod, Anna Jakubowska, Helena Rudnicka, Jan Lubinski, Rodney J Scott. Breast Cancer Res Treat 2015
66
16

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
580
15

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, Adriana Lopez, Vicente Valero, Christopher I Amos, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Banu K Arun. J Clin Oncol 2008
343
15

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
13

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, Chad A Livasy, Lynn G Dressler, David Cowan, Kathleen Conway, Gamze Karaca, Melissa A Troester, Chiu Kit Tse, Sharon Edmiston,[...]. JAMA 2006
13

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
13

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
E Comen, M Davids, T Kirchhoff, C Hudis, K Offit, M Robson. Breast Cancer Res Treat 2011
65
13

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Priyanka Sharma, Jennifer R Klemp, Bruce F Kimler, Jonathan D Mahnken, Larry J Geier, Qamar J Khan, Manana Elia, Carol S Connor, Marilee K McGinness, Joshua M W Mammen,[...]. Breast Cancer Res Treat 2014
91
13

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Soley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, Tunc Tasbas, Ugur Akar, Jennifer K Litton, E Lin, Constance T Albarracin, Funda Meric-Bernstam, Ana M Gonzalez-Angulo,[...]. Breast Cancer Res Treat 2011
64
12


BRCA in breast cancer: ESMO Clinical Practice Guidelines.
J Balmaña, O Díez, I T Rubio, F Cardoso. Ann Oncol 2011
114
12

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).
R Andrés, I Pajares, J Balmaña, G Llort, T Ramón Y Cajal, I Chirivella, E Aguirre, L Robles, E Lastra, P Pérez-Segura,[...]. Clin Transl Oncol 2014
20
40

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
Rachel Greenup, Adam Buchanan, Wendy Lorizio, Keelia Rhoads, Salina Chan, Tracey Leedom, Robin King, Jane McLennan, Beth Crawford, P Kelly Marcom,[...]. Ann Surg Oncol 2013
120
12

Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, Joel Parker, Trevor Hastie, J S Marron, Andrew Nobel, Shibing Deng, Hilde Johnsen, Robert Pesich, Stephanie Geisler,[...]. Proc Natl Acad Sci U S A 2003
10

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, Aron C Eklund, Zhigang C Wang, Zoltan Szallasi, Qiyuan Li, Nicolai Juul, Chee-Onn Leong, Diana Calogrias, Ayodele Buraimoh,[...]. J Clin Oncol 2010
639
10

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Nazneen Rahman, Sheila Seal, Deborah Thompson, Patrick Kelly, Anthony Renwick, Anna Elliott, Sarah Reid, Katarina Spanova, Rita Barfoot, Tasnim Chagtai,[...]. Nat Genet 2007
644
10

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Florentia Fostira, Marianthi Tsitlaidou, Christos Papadimitriou, Maroulio Pertesi, Eleni Timotheadou, Alexandra V Stavropoulou, Stavros Glentis, Evangelos Bournakis, Mattheos Bobos, Dimitrios Pectasides,[...]. Breast Cancer Res Treat 2012
60
11

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
William D Foulkes, Ingunn M Stefansson, Pierre O Chappuis, Louis R Bégin, John R Goffin, Nora Wong, Michel Trudel, Lars A Akslen. J Natl Cancer Inst 2003
693
10

Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
James D Fackenthal, Olufunmilayo I Olopade. Nat Rev Cancer 2007
280
10

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, Tomasz Huzarski, Ewa Grzybowska, Magdalena Budryk, Malgorzata Stawicka, Tomasz Mierzwa, Marek Szwiec, Rafal Wisniowski, Monika Siolek,[...]. J Clin Oncol 2010
367
10

Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
J Peto, N Collins, R Barfoot, S Seal, W Warren, N Rahman, D F Easton, C Evans, J Deacon, M R Stratton. J Natl Cancer Inst 1999
629
9

Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth. Nat Rev Cancer 2004
9


Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
9

Genetic susceptibility to triple-negative breast cancer.
Kristen N Stevens, Celine M Vachon, Fergus J Couch. Cancer Res 2013
118
9

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
9

Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.
Seth Rummel, Erika Varner, Craig D Shriver, Rachel E Ellsworth. Breast Cancer Res Treat 2013
35
17

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
9

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
9

The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
C Villarreal-Garza, J N Weitzel, M Llacuachaqui, E Sifuentes, M C Magallanes-Hoyos, L Gallardo, R M Alvarez-Gómez, J Herzog, D Castillo, R Royer,[...]. Breast Cancer Res Treat 2015
42
14

Prognostic markers in triple-negative breast cancer.
Emad A Rakha, Maysa E El-Sayed, Andrew R Green, Andrew H S Lee, John F Robertson, Ian O Ellis. Cancer 2007
863
7

19p13.1 is a triple-negative-specific breast cancer susceptibility locus.
Kristen N Stevens, Zachary Fredericksen, Celine M Vachon, Xianshu Wang, Sara Margolin, Annika Lindblom, Heli Nevanlinna, Dario Greco, Kristiina Aittomäki, Carl Blomqvist,[...]. Cancer Res 2012
75
7

BRCA2 mutations and triple-negative breast cancer.
Peter Meyer, Katharina Landgraf, Bernhard Högel, Wolfgang Eiermann, Beyhan Ataseven. PLoS One 2012
29
17

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
319
7


Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
7

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Hanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, Marijke Wasielewski, Anja de Snoo, Rogier Oldenburg, Antoinette Hollestelle, Mark Houben, Ellen Crepin, Monique van Veghel-Plandsoen,[...]. Nat Genet 2002
767
7

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.